The Government of India has published a comprehensive advisory regarding GLP-1 medications, emphasizing their increasing application in treating type 2 diabetes and obesity, while also cautioning about the associated risks and potential for misuse. As the...
India is currently grappling with a significant obesity crisis, with statistics indicating that one in four Indians is classified as overweight. This troubling trend is often misinterpreted as merely a lifestyle choice rather than being recognized...
Medications initially developed for managing diabetes and obesity are broadening their therapeutic applications. Recently, treatments based on the hormone GLP-1 have demonstrated benefits not...
The Indian healthcare market is bracing for a significant change as more than twenty generic variants of semaglutide, a highly sought-after drug for obesity...
India is developing its first National Obesity Guidelines after Prime Minister Narendra Modi’s Independence Day warning that obesity has become a “silent crisis” for...
American कंपनी Eli Lilly ने भारत में वजन घटाने की दवा Mounjaro लॉन्च की, जिसकी कीमत₹14,000 से ₹17,500 प्रति माह होगी। यह दवा Blood Sugar कंट्रोल और भूख कम करने में मदद करतीहै। Obesity और Diabetes से जूझ रहे लोगों के लिए यह एक क्रांतिकारी कदम है।
Eli Lilly Weight-Loss Drug अब भारत में...
